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~bstract The laminin (zl chain carhoxyl-terminal globular 
domain (G domain) contains multiple biological activities. 
Recently, we identified five cell binding sequences from the G 
domain by screening with overlapping 12-mer peptides encom- 
passing the entire domain. The structures of these five sequences 
in the ¢zl chain are conserved in the corresponding regions of the 
different laminin (z chains. Here we characterize the adhesion 
activities of the corresponding peptide segments from both the 
mouse laminin o~2 chain and Drosophila laminin ~ chain using 
peptide-coated plastic plates and peptide-conjugated Sepharose 
beads. Using several cell lines, the laminin ft.2 chain peptides 
~howed cell attachment and/or spreading activities with cell type 
~pecificities. Cell spreading on MG-10 was inhibited by integrin 
antibodies. Four of the Drosophila iaminin peptides showed cell 
attachment activities. These results suggest that biologically 
active regions in the G domain are conserved in the laminin ~1 
and (x2 chains, and that these regions in laminin play an 
~mportant role in cell surface receptor interactions. 
Key words: Laminin; Synthetic peptide; Cell attachment; 
~asement membrane; Integrin 
I. Introduction 
Laminins are major components of basement membrane, 
:he thin extracellular matrix which underlies all epithelia 
md surrounds muscle, peripheral nerve, and fat cells [1-3]. 
Laminin-I consists of c~l, [31 and y1 chains, which assemble 
nto a triple-stranded coiled-coil structure in the long arm to 
"orm a cross-like structure (Fig. 1) [3]. Laminin-1 has diverse 
~iological activities including promotion of cell adhesion, 
~preading, rowth, neurite outgrowth, tumor metastasis, and 
:ollagenase IV activity [1]. Several laminin isoforms have been 
identified with at least eight genetically distinct chains [4]. 
Laminin-2 consisting of c~2, 131 and T 1 chains is located in 
the basement membranes of nervous tissue, Schwann cells, 
muscle, trophoblast and placenta [5,6]. The laminin cd chain 
carboxyl-terminal g obular domain (G domain) has been 
shown to be important for biological activities. The E8 frag- 
ment containing the C-terminal a-helical triple stranded 
coiled-coil domain and the N-terminal G domain possesses 
the major cell binding activity which is mediated, in part, 
through c(6131 integrin [7-9]. Recombinant and reconstitution 
experiments have suggested that this activity may be depen- 
dent, in part, on protein conformation [10,11]. 
Several active sequences on laminin chains have been iden- 
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tiffed using synthetic peptides [12,13]. Recently we identified 
five cell binding sites (AG-10, AG-22, AG-32, AG-56 and 
AG-73) from the laminin c(1 chain G domain by screening 
113 overlapping synthetic peptides attached to beads followed 
by further assays of the free peptides (Fig. 1) [14]. Several 
additional in vitro biological activities of the five peptides 
were evaluated and one of the peptides (AG-73) was active 
for neurite outgrowth [15]. Cell spreading on AG-10 and AG- 
32 was inhibited by c~6131 integrin antibodies whereas the ac- 
tivities of the these other peptides were not blocked [14]. 
These five active peptides have sequence homologies with their 
corresponding regions on the human laminin c(l and c(2 
chains, the mouse laminin e(2 chain and the Drosophila lami- 
nin e~ chain. Positive amino acids (arginine residues) in the 
minimum active sequences of AG-10, AG-32 and AG-73 
(SIYITRF, IAFQRN and LQVQLSIR, respectively) are com- 
pletely conserved among the different species and different 
laminin c( chains. Since the sequences are structurally con- 
served, we determined if the biological activities of the differ- 
ent laminin c( chains were conserved. Using peptide-coated 
plates and peptide-conjugated Sepharose beads, synthetic pep- 
tides from the mouse c(2 chain and Drosophila ct chain which 
correspond to known active sequences in the mouse c(1 chain 
were evaluated for cell adhesive activities. 
2. Materials and methods 
2. I. Synthetic peptides and laminins 
All peptides were manually synthesized by the 9-fluorenylmethoxy- 
carbonyl (Fmoc) based solid-phase strategy and prepared as the C- 
terminal amide form as described previously [14]. The respective ami- 
no acids were condensed manually in a stepwise manner using a 
tris(alkoxy)benzylamine resin. For condensation, diisopropylcarbodi- 
imide/N-hydroxybenzotriazole was employed, and for deprotection of 
N~-Fmoc groups, 20% piperidine in dimethylformamide was em- 
ployed. The following side chain protecting roups were used: Asn, 
Gln and His, trityl; Asp, Glu, Ser, Thr and Tyr, t-butyl; Arg, 
2,2,5,7,8-pentamethylchroman-6-sulfonyl; Lys, t-butoxycarbonyl. 
Protected peptide resins were treated with trifluoroacetic acid-thioani- 
sole-m-cresol-ethanedithiol-H20 (80:5:5:5:5, v/v) at 20°C for 4 h. The 
resulting crude peptides were precipitated and washed with diethyl 
ether, then purified by reverse-phase high-performance liquid chroma- 
tography. Purity of the peptides was confirmed by analytical high- 
performance liquid chromatography. Identity of the peptides was con- 
firmed by amino acid analysis. Amino acid analyses were performed 
at the Faculty of Pharmaceutical Sciences, Kyoto University, Kyoto, 
Japan. Mouse laminin-1 was prepared from the Engelbreth-Holm- 
Swarm tumor as described previously [16]. 
2.2. Antibodies 
The rat monoclonal antibodies used were as follows: mAb 13, an 
antibody to the !31 integrin subunit [17], was a generous gift from Dr. 
S. K. Akiyama (NIH, Bethesda, MD) and GoH3, an anti-a6 integrin 
subunit antibody, was purchased from AMAC (Westbrook, ME). 
0014-5793/96l$12.00 ¢) 1996 Federation of European Biochemical Societies. All rights reserved. 
PH S00 1 4-5793(96)01 060-5 
38 M. Nomizu et aL/FEBS Letters 396 (1996) 37-42 
c~1 chain 
(4o0 kDa) 
YIGSR @ NH2 
/~lchaln '~  # 71 chain 
(200 kDa) . . . .  (200 kDa) 
/ 
v. / 
PDSGR 
IKVAV 
AG-10 ~ I I E8 
(s,v,r,F) ""-- - . . . .  
A .22 -----',JW fi AG -32 " - " - " 'w ' l~  G domain ,'-o=, J ' i _  ] . j  
AG-73 
(LQVQLSIR) 
Fig. 1. Structural model of laminin-l. The location of cell binding 
sites are indicated by arrows. YIGSR from Graf et al. [27], PDSGR 
from Kleinman et al. [28], IKVAV from Tashiro et al. [29], F-9 
(RYVVLPR) from Charonis et al. [30] and Skubitz et al. [31], RGD 
from Tashiro et al. [32], AG-10, AG-22, AG-32, AG-56, AG-73 
from Nomizu et al. [14]. E8 and E3 designate previously described 
proteolytic fragments active in cell adhesion [33]. The E8 and E3 
fragments and the G domain are indicated by square brackets. 
Mouse monoclonal antibodies used were: P1E6, an anti-c~2 integrin 
subunit antibody, and PIB5, an anti-~3 integrin subunit antibody. 
These antibodies and mouse pre-immune IgG were purchased from 
Life Technologies, Inc. (Gaithersburg, MD) and Sigma (St. Louis, 
MO). 
2.3. Preparation of peptide-bead~ 
The synthetic peptides, RGD sequence containing fibronectin pep- 
tide segment (FIB-l: YAVTGRGDSPAS) [14], and laminin-I were 
coupled to CNBr-activated Sepharose 4B (Pharmacia Biotech AB, 
Uppsala, Sweden) according to the manufacturer's instructions. The 
peptide solutions (1 ml, 1 mg/ml in PBS) or laminin-1 solution (1 ml, 
0.1 mg/ml in PBS) were mixed with 50 mg of the activated Sepharose 
beads. Ethanolamine-coupled beads were prepared as a control. 
Amounts of coupled peptide were determined by amino acid analysis 
and the all peptide-beads were coupled at 10 20/amol peptides per g 
of Sepharose beads. 
2.4. Cells and culture 
The following cells were used for this study: B16-FI0 mouse mel- 
anoma cells [18], HT-1080 human fibrosarcoma cells [19], C2C12 
mouse skeletal myoblasts (ATCC, CRL-1772), and RPMI 7951 hu- 
man melanoma cells (ATCC, HTB66). Cells were maintained in Dul- 
becco's modified Eagle's medium (DMEM, Gibco, Grand Island, NY) 
containing 10% fetal bovine serum (FBS, Hyclone, Logan, UT), 100 
units/ml penicillin, and 100 ~tg/ml streptomycin (Gibco, Grand Island, 
NY). 
2.5. Attachment assay 
Cell attachment was assayed in a round bottom 96-well plate (Im- 
mulon 2, Dynatech, Chantilly, VA) coated with either various 
amounts of synthetic peptides or laminin-1. The peptides or lami- 
nin-1 were dissolved in Milli-Q water and 50 ~tl of the solution was 
added to each well, followed by drying overnight. The wells were 
blocked by addition of 200 I.tl of 3% bovine serum albumin (BSA) 
in DMEM at 37°C for 1 h, then washed three times with DMEM 
containing 0.1% BSA. Cells, detached by 0.02% EDTA in PBS and 
resuspended in DMEM containing 0.1% BSA, were added (2 x 10410.2 
ml) to each well and incubated at 37°C for 1 h in 5% COs. The 
attached cells were stained with 200/al of 0.2% crystal violet aqueous 
Table 1 
Synthetic peptides and their cell attachment activities 
Peptide ~ Sequence b Residue': Cell attachment activity ~ 
Plate coat 
HT-1080 B16-F10 
Sepharose beads 
C2-C12 HT-1080 B16-F10 C2-C12 
AG-10 NRWHSIY ITRFG c~l : 2183-2194 ++ ++ ++ ++ ++ ++ 
MG-10 SYWYRIEASRTG c~2:2290-2301 + + ++ + ++ ++ 
DG-10 GRWYQAVVDRMG Da:  2761-2772 + + + + + + 
AG-22 SSFHFDGSGYAM ~1:2290-2301 + + + 
MG-22 GT IQFDGEGYAL  c~2:2335 2346 + + + 
DG-22 TGLRFKGNGYVQ Dec: 2877-2888 + + + + ++ ++ 
AG-32 TWYKIAFQRNRK ~1:2369-2380 + ++ ++ ++ ++ ++ 
MG-32 KWKAFTLSRIQK ~x2:2417-2428 + + ++ ++ ++ ++ 
DG-32 QWHKVQAERENR Dcc: 2959-2970 + + + + + + 
AG-56 SLVRNRRVITIQ ~1:2570-2581 + + + + + + 
MG-56 HVERTRGIFTVQ c~2: 2623-2634 + + + + + + 
DG-56 TVQHTQGELRLT  Da:  3038 3049 - 
AG-73 RKRLQVQLS IRT  ~1:2719-2730 +++ +++ +++ +++ +++ +++ 
MG-73 KNRLTIELEVRT c~2:2780-2791 +++ +++ +++ +++ +++ +++ 
DG-73 RRHHDIGISFRT Dcz: 3370-3381 + + + ++ ++ ++ 
MG-73S RTLEVINTKLER - - 
FIB-1 YAVTGRGDSPAS +++ +++ +++ 
Laminin-1 ' +++ +++ +++ +++ +++ +++ 
~AG-10, 22, 32, 56 and 73: mouse laminin c~l chain peptide segments. MG and DG peptides: mouse laminin cz2 and Drosophila laminin c~ chains, 
respectively. 
I'Sequences of the synthetic peptides are given in the single-letter code. Minimum active sites of laminin-1 peptides previously determined are shown 
in bold. All peptides have C-terminal amides. 
':Residues of peptides are described, czl, mouse laminin czl chain [34]; e~2, mouse laminin c~2 chain [23]; Dcz, Drosophila laminin cz chain [24]. 
4For cell attachment assays, various amounts of laminin-1 and peptides were coated on the wells as described in Section 2. In all cases, the 
biological activities were quantitated and peptide activities were evaluated relative to the activity observed with laminin-l, as shown in Fig. 2. Cell 
attachment on the following subjective scale: +++, adhesion comparable to that on laminin-1 ; ++, adhesion apparent but weaker than on laminin- 
1 ; +, adhesion level is low; , no adhesion. 
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i ig. 2. Attachment of BI6-F10 cells and C2C12 cells to peptide-coated plates. (A,B) B16-F10 mouse melanoma cell attachment to AG-peptides 
nd MG-peptides, respectively. (C,D) C2C12 mouse skeletal myoblast cell attachment to AG-peptides and MG-peptides, respectively. Peptides 
nd laminin-1 were dissolved in H20, added to 96-well tissue culture plates, and dried overnight. BI6-F10 mouse melanoma cells and C2C12 
~ouse skeletal myoblasts were added and the number of attached cells was assessed by crystal violet staining. Each value represents he mean 
, f three separate determinations+S.E.M. Duplicate xperiments gave similar results. 
~olution in 20% methanol for 10 rain. After washing, 200 Ixl of 1% 
\DS was used to dissolve the cells and the optical density at 560 nm 
was measured in a Titertek Multiskan. Peptide-coated wells without 
, ells were processed simultaneously to subtract he background be- 
, ause some peptides at higher concentrations were stained with crystal 
, iolet. Coating efficiencies (%) of the synthetic peptides were deter- 
~lined using fluorescamine as shown previously [20,21]. Coating effi- 
,, iencies of laminin-1 (5 pg/well) and the synthetic peptides (50 I.tg/well) 
.,:ere 12.1% (laminin-1), 6.7% (AG-10), 0.1% (AG-22), 0.1% (AG-32), 
, .2% (AG-56), 12.5% (AG-73), 5.9% (MG-10), 3.9% (MG-22), 0.2% 
, VIG-32), 0.2% (MG-56), 14.5% (MG-73), 0.2% (MG-73S), 0.2% 
DG-10), 0.2°/,, (DG-22), 0.1% (DG-32), 0.1% (DG-56), 0.3% (DG- 
3), 0.1% (FIB-l). 
.6. Cell attachment assay using peptide-beads 
Cell attachment to peptide-beads was assayed in 96-well plates 
,hich were blocked with DMEM containing 3% BSA. Peptide-beads 
20 pl, 100 mg bead/ml in PBS) and cells (100 pl, 1x10~/ml in 
I)MEM containing 0.1% BSA) were added to the 96-well plates and 
~ lcubated at 37°C in 5% CO2 for 2 h. The beads were stained with 
, rystal violet and washed with H20 (200 ~tl x 2 times). Cell attachment 
) the peptide-beads was analyzed under the microscope. 
.:. 7. Cell spreading assays 
Wells of a flat bottom 96-well plate (Immulon 2, Dynatech, Chan- 
tilly, VA) were coated with various amounts of either laminin-1 or 
synthetic peptides, then incubated for 2 h or dried overnight. Wells 
were subsequently blocked with 3% BSA in DMEM for 1 h at room 
temperature. RPMI 7951 human melanoma cells were detached with 
trypsin and allowed to recover in the presence of 10% FBS for 30 rain 
at 37°C in 5% CO2. After washing twice with DMEM containing 
0.1%BSA, cells were placed in the coated wells at 5x 103 cells/well 
in 100 ktl of DMEM containing 0.1%BSA. After 45 rain of incubation 
at 37°C, the cells were fixed with 3% formaldehyde and stained with 
0.004% crystal violet, and the percentage of spreading cells was 
counted using phase contrast microscopy [14]. 
3. Results 
The segments of the five laminin ctl chain-derived peptides 
previously identified as active for cell attachment (AG-10, 
AG-22,  AG-32, AG-56, and AG-73) [14] are listed in Table 
1. Laminin ct2 chain peptides (MG-10, MG-22, MG-32, MG-  
56 and MG-73) and Drosophila tx chain peptides (DG-10, 
DG-22, DG-32, DG-56 and DG-73), which was correspond- 
ing segments of the active sequences in laminin a l  chain, were 
prepared (Table 1). As controls, the Arg-Gly-Asp (RGD)  se- 
quence containing fibronectin peptide segment (FIB-1 : 
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Fig. 3. Effect of peptides and integrin antibodies on RPMI 7951 human melanoma cell spreading. (A) Effect of different concentrations of lami- 
nin-1 and synthetic peptides on cell spreading. (B) Inhibitory effect of anti-integrin antibodies. Cell spreading assays were performed on un- 
treated controls (a), or in the presence of mouse pre-immune IgG (2 ~tg/ml) (b), anti-131 integrin monoclonal antibody (mAb 13, 67 ~tg/ml) (c), 
anti-a2 integrin monoclonal antibody ascites (P1E6, 1 : 33 dilution) (d), anti-a3 integrin monoclonal antibody ascites (P1B5, 1 : 33 dilution) (e), 
and anti-~6 integrin monoclonal antibody (GoH3, 2 ~tg/ml) (f). The amounts of coated peptides were 2 ~tg/well for laminin-1 AG-73 and MG- 
73,50 ~tg/well for AG-10, and 100 p.g/well for MG-10. Each value represents the mean of three separate determinations + S.E.M. Duplicate ex- 
periments gave similar results. 
YAVTGRGDSPAS) [14], and a scrambled MG-73 peptide, 
MG-73S, were prepared. 
Cell attachment activities of the laminin c~l and c~2 chain G 
domain peptides were evaluated on peptide-coated plastic 
plate using B16-F10 mouse melanoma cells and C2C12 mouse 
skeletal myoblasts (Fig. 2). The laminin c~l chain peptides, 
AG-peptides, showed dose-dependent cell attachment activ- 
ities for both B16-F10 and C2C12 cells as expected (Fig. 
2A,C). C2C12 cells adhered equally well to MG- (Fig. 2D) 
and to AG peptides, 10 and 73, better to AG-22 than MG-22 
and less well to MG-32 and 56 relative to the AG peptides. 
However, B16-F10 cells were found to adhere weakly to MG 
peptides (Fig. 2B) except for MG-73 when compared to AG- 
peptides. AG-22 and AG-56 had weak activity relative to the 
other AG peptides for B16-F10 cells. Both B16-F10 and 
C2C12 cells did not attach to a sequentially scrambled MG- 
73 peptide, MG-73S (Fig. 2B,D). MG-10, MG-22, MG-32 
and MG-56 showed dose-dependent cell attachment activity 
to both B16-F10 and C2C12 cells, and C2C12 cells showed 
stronger attachment activities on these peptides compared to 
those of BI6-F10 cells. The MG-peptides interacted more fa- 
vorably with muscle cells rather than melanoma cells. 
Cell attachment activities of the synthetic peptides from the 
mouse e~l and a2 chains and from the Drosophila e~ chain 
(Table 1) were tested using HT-1080 human fibrosarcoma 
cells, B16-F10 mouse melanoma cells and C2C12 cells (Table 
1). Four of the Drosophila a chain peptides, DG-10, DG-22, 
DG-32 and DG-73 showed cell attachment activities, whereas 
DG-56 was not active. An RGD sequence containing fibro- 
nectin peptide segment, FIB-l, did not show cell attachment 
activity in this assay (Table 1), possibly due to conformation 
changes when dried on the dish. 
Cell spreading activity of AG and MG peptides was as- 
sessed using RPMI 7951 human melanoma cells. RPMI 
7951 cells attached and spread in a dose-dependent manner 
on AG-10, AG-73, MG-10, and MG-73 peptide-coated plates 
(Fig. 3A). RPMI 7951 cells spread weakly on AG-32- and 
MG-32-coated plates (Fig. 3A) and did not spread on AG- 
22-, MG-22-, AG-56-, MG-56-coated plates (data not shown). 
The effects of integrin antibodies on cell spreading mediated 
by AG-10, MG-10, AG-73 and MG-73 were tested using anti- 
[31, e~2, c~3 and a6 integrin antibodies (Fig. 3B). The anti-131 
integrin antibody inhibited laminin-l-mediated cell spreading. 
Cell spreading mediated by AG-10 and MG-10 was inhibited 
by anti-I]l integrin antibodies. Anti-c~3 and c~6 integrin anti- 
bodies partially inhibited AG-10- and MG-10-mediated cell 
spreading. While anti-131, a2, a3 and a6 integrin antibodies 
did not affect AG-73- and MG-73-mediated cell spreading. 
Next, we evaluated cell adhesion to covalently conjugated 
peptides on Sepharose beads (Fig. 4). All synthetic peptides 
listed in Table 1 were conjugated to Sepharose beads and their 
cell attachment activities were tested using HT-1080 human 
fibrosarcoma cells, B16-F10 mouse melanoma cells and 
C2C12 cells (Table 1). B16-F10 cells attached and spread on 
the Laminin-1 and FIB-1 conjugated Sepharose beads (Fig. 
4I,J), but the cells did not attach on control ethanolamine 
conjugated beads or on the scramble MG-73 (MG-73S) beads 
(Fig. 4K,L). AG-10, AG-32 and AG-73 conjugated Sepharose 
beads showed cell attachment and spreading (Fig. 4A,B,D). 
The cells weakly attached on AG-56 beads (Fig. 4C), and 
none of the cells attached on AG-22 beads. MG-10, MG-32 
and MG-73 beads showed cell attachment and spreading (Fig. 
4E,F,H) and MG-56 beads showed weak cell attachment ac- 
tivity (Fig. 4G), while few attached cells were observed on 
MG-22 beads. DG-10, DG-22 and DG-73 showed cell attach- 
ment and spreading activities, however, few cells were ob- 
served on DG-32 and DG-56 conjugated Sepharose beads. 
These data demonstrate hat the a2 and Drosophila e~ homo- 
logues of the laminin cxl chain active peptides are active in 
attachment. 
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I 
Zig. 4. Adhesion of BI6-F10 cells on peptide-conjugated Sepharose beads. B16-FI0 mouse melanoma cells were allowed to attach to peptide- 
:onjugated Sepharose beads for 2 h and stained with crystal violet. A, AG-10; B, AG-32; C, AG-56; D, AG-73; E, MG-10: F, MG-32; G, 
riG-56; H, MG-73: I, laminin-1; J, FIB-l; K, ethanolamine: L, MG-73S. 
L Discussion 
Here we have shown cell attachment activities of small pep- 
ide segments on peptide-coated plates and on peptide-conju- 
gated Sepharose beads. The peptide-conjugated Sepharose 
~ead assay was originally used for evaluating the biological 
tctivities of fibronectin-derived active segments [22]. An 
RGD-containing fibronectin segment, FIB-l, did not display 
-ell attachment activity in the peptide-coated plate assay, but 
lid show strong cell attachment and spreading activity in the 
~eptide-conjugated S pharose bead assay. The RGD peptide 
s active in solution to inhibit cell attachment and spreading 
~n a fibronectin-coated dish. It seems that peptides aggregate 
~n the plate and may be less likely to form active conforma- 
ions, whereas peptides are flexible on Sepharose beads and 
tble to form active conformations [23]. The cell attachment 
~ctivities on peptide-coated plates are also dependent, in part, 
~n the coating efficiencies of the peptides. It is difficult to 
:ompare directly the cell attachment activities among all the 
~eptides since they showed different coating efficiencies (from 
).1 to 14.5% depending of the peptide). The peptide-coated 
~late assay is quite useful for comparing cell attachment ac- 
ivity among peptides having similar coating efficiencies. It is 
also possible to perform dose-response type assays using the 
peptide-coated dishes whereas uch a dose-response test would 
be difficult with the beads. The Sepharose bead method is 
useful for evaluating biological activities of short peptides 
which require active conformations and which show low coat- 
ing efficiency to plastic dish. In this study, we use both a 
peptide-coating assay and a peptide-conjugated bead assay 
for evaluating cell adhesive activities of the laminin-derived 
synthetic peptides to address these questions of conformation 
and coating efficiencies of the various peptides, The data as 
noted below indicate that coating may not have been a sig- 
nificant factor since AG-22 showed low activity with B16-F10 
cells and high activity with C2C12 cells. These data demon- 
strate an important effect due to cell type specificity in adhe- 
sion rather than peptide coating. Additional examples of cell 
type specificity are noted with the MG peptides as well. 
We previously identified five different cell binding sequences 
from the mouse laminin c~l chain G domain by systematic 
screening using a large set of overlapping synthetic peptide- 
beads and free peptides [14]. These mouse laminin c~l chain 
active sequences are highly conserved in the corresponding 
regions of the different laminin c~ chains (human ctl, human 
c~2, mouse ct2, and Drosophila et chains). Here we have char- 
acterized the cell adhesive activities of the corresponding pep- 
tide segments from the mouse laminin e~2 chain [24] and Dro- 
sophila laminin ct chain [25]. The laminin c~2 chain peptides 
(MG-10, MG-22, MG-32, MG-56 and MG-73) showed cell 
attachment activity in the peptide-coated plate assay and in 
the peptide-bead assay with the exception of MG-22 which 
42 
was not active in the bead assay. The AG peptides attached 
similarly to B16-F10 and C2C12 cells, however, the MG pep- 
tides except for MG-73 showed weaker B16-F10 cell attach- 
ment activities compared to those of C2C12 cell attachment. 
Laminin ~x2 chain is mainly located in basement membranes 
of nervous tissue, Schwann cells, muscle, trophoblast and pla- 
centa [5,6]. MG-10, MG-32 and MG-73 peptides howed cell 
attachment and spreading activities on both peptide-coated 
plates and peptide-conjugated Sepharose bead assay with 
cell type specificities. The MG peptides eem to have more 
affinity to the muscle-derived cell line, C2C12, compared to 
melanoma cells. These data suggest that the MG peptides may 
have cell type specifieities for interactions with cell surface 
receptors. 
Cell spreading of AG-10 and AG-32 was previously shown 
to be mediated by a6131 integrin [14]. In the present study, cell 
spreading of AG-10 and MG-10 was inhibited by 131 integrin 
antibody and weakly inhibited by c~3 and ~x6 integrin antibod- 
ies. While AG-73 and MG-73 showed strong cell spreading 
activity, tx2, t~3, ct6, and 131 integrin antibodies did not inhibit 
the activity. These results suggest hat cell spreading on AG- 
10 and MG-10 is mediated by similar integrin subunits and 
the adhesion and spreading on AG-73 and MG-73 probably is 
mediated by either a different integrin and/or a non-integrin 
receptor. 
Four Drosophila laminin ct chain peptides (DG-10, DG-22, 
DG-32 and DG-73) were also found to have cell attachment 
activity, but these activities were weaker than those of the 
corresponding mouse ctl and ct2 peptides. Recently, we found 
that the DG-22 peptide promoted neurite outgrowth in Dro- 
sophila primary cell cultures, whereas the corresponding 
mouse laminin ctl chain peptide, AG-22, did not show this 
activity [26]. These results uggest that the biological activities 
of the five sites are conserved in the laminin c~ chain family 
with cell type specificities, and that these five regions may play 
an important role in laminin interactions with cell surface 
receptors. 
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